You are not currently logged in.
Access JSTOR through your library or other institution:
Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) Virus
Daniel E. Dulek, John V. Williams, C. Buddy Creech, Alynna K. Schulert, Haydar A. Frangoul, Jennifer Domm, Mark R. Denison and James D. Chappell
Clinical Infectious Diseases
Vol. 50, No. 11 (1 June 2010), pp. 1493-1496
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/25679895
Page Count: 4
You can always find the topics here!Topics: Influenza, H1N1 subtype influenza A virus, Viruses, Pandemics, Infections, Immunosuppressants, Polymerase chain reaction, Nervous system diseases, Viral diseases, Pediatrics
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.
Clinical Infectious Diseases © 2010 Oxford University Press